SuperGen Buys U.K.'s Astex, Building Cash-Rich Oncology Play
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal brings private Astex a long-sought NASDAQ listing and beefs up cash-rich SuperGen's lackluster pipeline.
You may also be interested in...
Astex Aims To Make Cancer Drug Resistance Futile
“Using our drugs, we’re trying to facilitate the old drugs or help them work better longer,” Astex’s Lyons said. Astex, AstraZeneca and Novartis all presented data on compounds from Astex’s fragment-based drug discovery platform at the recent American Association for Cancer Research meeting in Washington, D.C.
SuperGen, Astex Management Sell Merger Strategy To Investors
After announcing a merger of the biotechs, management sought to convince investors the combination offers the best long-term value for both sides during an analyst day.
SuperGen, Astex Management Sell Merger Strategy To Investors
After announcing a merger of the biotechs, management sought to convince investors the combination offers the best long-term value for both sides during an analyst day.